Skip Navigation



Annals of Oncology Advance Access published online on November 2, 2006
Annals of Oncology, doi:10.1093/annonc/mdl401
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
18/2/282    most recent
mdl401v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hilpert, F.
Right arrow Articles by Pfisterer, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hilpert, F.
Right arrow Articles by Pfisterer, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology
Received June 15, 2006
Revised September 11, 2006
Accepted September 18, 2006

original article

Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged ≥70 years with advanced ovarian cancer--a study by the AGO OVAR Germany

F. Hilpert 1 *, A. du Bois 2, E. R. Greimel 3, J. Hedderich 4, G. Krause 1, L. Venhoff 1, S. Loibl 5, and J. Pfisterer 6

1 Klinik für Gynäkologie und Geburtshilfe, Campus Kiel, Universitätsklinikum Schleswig-Holstein, Kiel
2 Klinik für Gynäkologie und gynäkologische Onkologie, HSK Dr Horst Schmidt Klinik, Wiesbaden, Germany
3 Universitätsklinik für Frauenheilkunde und Geburtshilfe, Medizinische Universität Graz, Graz, Austria
4 Institut für Medizinische Informatik und Statistik, Campus Kiel, Universitätsklinikum Schleswig-Holstein, Kiel
5 Klinik für Gynäkologie und Geburtshilfe, Klinikum der J.W. Goethe-Universität, Frankfurt/M.
6 Klinik für Gynäkologie und Geburtshilfe, Campus Kiel, Universitätsklinikum Schleswig-Holstein, Kiel; Frauenklinik, Universitätsklinikum Mannheim, Mannheim, Germany

* To whom correspondence should be addressed.
F. Hilpert, E-mail: fhilpert{at}email.uni-kiel.de


  Abstract

Background: The purpose of the study was to evaluate first-line platinum/paclitaxel (Taxol) under phase III trial conditions in ovarian cancer (OC) patients aged ≥70 years.

Patients and methods: Phase III results of 779 patients with OC International Federation of Gynecology and Obstetrics (FIGO) stage IIB/IV treated with cisplatin/paclitaxel versus carboplatin/paclitaxel were retrospectively analyzed according to feasibility, toxicity (National Cancer Institute Common Toxicity Criteria) and quality of life (QoL) [European Organization for Research and Treatment of Cancer QoL questionnaire (EORTC QLQ-C30)] in patients aged <70 or ≥70 years.

Results: One hundred and three (13%) patients were aged ≥70 years. Patient characteristics (<70 versus ≥70 years) showed significant differences with regard to Eastern Cooperative Oncology Group performance status, residual disease and constitutional factors but not to FIGO stage, histology or grading. Elderly patients received 98%, 100% and 96% of the recommended paclitaxel, carboplatin and cisplatin dose, respectively, per cycle. Early discontinuation was more frequent in elderly, although QoL, nonhematological and hematological toxicity were comparable between elderly and younger patients, except for febrile neutropenia (5% versus <1%, P = 0.005). There were no significant differences with regard to cycle delays, dose reductions or the use of granulocyte colony-stimulating factor and antibiotics.

Conclusion: Platinum/paclitaxel appeared to be feasible and tolerable in elderly patients under clinical trial conditions, but there seems to be a different investigators' estimation of toxicity and less intention to maintain trial treatment in elderly.

Keywords: elderly patients; ovarian cancer; phase III trial; platinum/paclitaxel.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.